Fluidigm acquisition positive, says Oppenheimer


After Fluidigm agreed to buy DVS Sciences, Oppenheimer expects existing high customer overlap between the companies to accelerate product integration and sales synergies between them. The firm believes that DVS' CyTOF single-cell analysis system has certain advantages over traditional flow cytometry systems. It keeps an Outperform rating on Fluidigm.

View Comments (0)